Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer

Eduardo C. Salido, Xiao M. Li, Yang Lu, Xia Wang, Alfredo Santana, Namita Roy-Chowdhury, Armando Torres, Larry J. Shapiro, Jayanta Roy-Chowdhury

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Mutations in the alanine-glyoxylate amino transferase gene (AGXT) are responsible for primary hyperoxaluria type I, a rare disease characterized by excessive hepatic oxalate production that leads to renal failure. We generated a null mutant mouse by targeted mutagenesis of the homologous gene, Agxt, in embryonic stem cells. Mutant mice developed normally, and they exhibited hyperoxaluria and crystalluria. Approximately half of the male mice in mixed genetic background developed calcium oxalate urinary stones. Severe nephrocalcinosis and renal failure developed after enhancement of oxalate production by ethylene glycol administration. Hepatic expression of human AGT1, the protein encoded by AGXT, by adenoviral vector-mediated gene transfer in Agxt-/- mice normalized urinary oxalate excretion and prevented oxalate crystalluria. Subcellular fractionation and immunofluorescence studies revealed that, as in the human liver, the expressed wild-type human AGT1 was predominantly localized in mouse hepatocellular peroxisomes, whereas the most common mutant form of AGT1 (G170R) was localized predominantly in the mitochondria.

Original languageEnglish (US)
Pages (from-to)18249-18254
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number48
DOIs
StatePublished - Nov 28 2006

Fingerprint

Primary Hyperoxaluria
Oxalates
Genes
Transferases
Alanine
Renal Insufficiency
Liver
Hyperoxaluria
Nephrocalcinosis
Calcium Oxalate
Urinary Calculi
Peroxisomes
Ethylene Glycol
Embryonic Stem Cells
Rare Diseases
Mutagenesis
Fluorescent Antibody Technique
Mitochondria
Alanine-glyoxylate transaminase
Mutation

Keywords

  • Gene therapy
  • Knockout mouse
  • Nephrocalcinosis
  • Oxalate
  • Urolithiasis

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. / Salido, Eduardo C.; Li, Xiao M.; Lu, Yang; Wang, Xia; Santana, Alfredo; Roy-Chowdhury, Namita; Torres, Armando; Shapiro, Larry J.; Roy-Chowdhury, Jayanta.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 48, 28.11.2006, p. 18249-18254.

Research output: Contribution to journalArticle

Salido, Eduardo C. ; Li, Xiao M. ; Lu, Yang ; Wang, Xia ; Santana, Alfredo ; Roy-Chowdhury, Namita ; Torres, Armando ; Shapiro, Larry J. ; Roy-Chowdhury, Jayanta. / Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. In: Proceedings of the National Academy of Sciences of the United States of America. 2006 ; Vol. 103, No. 48. pp. 18249-18254.
@article{d519ba6adb194d7a990748a619abd495,
title = "Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer",
abstract = "Mutations in the alanine-glyoxylate amino transferase gene (AGXT) are responsible for primary hyperoxaluria type I, a rare disease characterized by excessive hepatic oxalate production that leads to renal failure. We generated a null mutant mouse by targeted mutagenesis of the homologous gene, Agxt, in embryonic stem cells. Mutant mice developed normally, and they exhibited hyperoxaluria and crystalluria. Approximately half of the male mice in mixed genetic background developed calcium oxalate urinary stones. Severe nephrocalcinosis and renal failure developed after enhancement of oxalate production by ethylene glycol administration. Hepatic expression of human AGT1, the protein encoded by AGXT, by adenoviral vector-mediated gene transfer in Agxt-/- mice normalized urinary oxalate excretion and prevented oxalate crystalluria. Subcellular fractionation and immunofluorescence studies revealed that, as in the human liver, the expressed wild-type human AGT1 was predominantly localized in mouse hepatocellular peroxisomes, whereas the most common mutant form of AGT1 (G170R) was localized predominantly in the mitochondria.",
keywords = "Gene therapy, Knockout mouse, Nephrocalcinosis, Oxalate, Urolithiasis",
author = "Salido, {Eduardo C.} and Li, {Xiao M.} and Yang Lu and Xia Wang and Alfredo Santana and Namita Roy-Chowdhury and Armando Torres and Shapiro, {Larry J.} and Jayanta Roy-Chowdhury",
year = "2006",
month = "11",
day = "28",
doi = "10.1073/pnas.0607218103",
language = "English (US)",
volume = "103",
pages = "18249--18254",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "48",

}

TY - JOUR

T1 - Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer

AU - Salido, Eduardo C.

AU - Li, Xiao M.

AU - Lu, Yang

AU - Wang, Xia

AU - Santana, Alfredo

AU - Roy-Chowdhury, Namita

AU - Torres, Armando

AU - Shapiro, Larry J.

AU - Roy-Chowdhury, Jayanta

PY - 2006/11/28

Y1 - 2006/11/28

N2 - Mutations in the alanine-glyoxylate amino transferase gene (AGXT) are responsible for primary hyperoxaluria type I, a rare disease characterized by excessive hepatic oxalate production that leads to renal failure. We generated a null mutant mouse by targeted mutagenesis of the homologous gene, Agxt, in embryonic stem cells. Mutant mice developed normally, and they exhibited hyperoxaluria and crystalluria. Approximately half of the male mice in mixed genetic background developed calcium oxalate urinary stones. Severe nephrocalcinosis and renal failure developed after enhancement of oxalate production by ethylene glycol administration. Hepatic expression of human AGT1, the protein encoded by AGXT, by adenoviral vector-mediated gene transfer in Agxt-/- mice normalized urinary oxalate excretion and prevented oxalate crystalluria. Subcellular fractionation and immunofluorescence studies revealed that, as in the human liver, the expressed wild-type human AGT1 was predominantly localized in mouse hepatocellular peroxisomes, whereas the most common mutant form of AGT1 (G170R) was localized predominantly in the mitochondria.

AB - Mutations in the alanine-glyoxylate amino transferase gene (AGXT) are responsible for primary hyperoxaluria type I, a rare disease characterized by excessive hepatic oxalate production that leads to renal failure. We generated a null mutant mouse by targeted mutagenesis of the homologous gene, Agxt, in embryonic stem cells. Mutant mice developed normally, and they exhibited hyperoxaluria and crystalluria. Approximately half of the male mice in mixed genetic background developed calcium oxalate urinary stones. Severe nephrocalcinosis and renal failure developed after enhancement of oxalate production by ethylene glycol administration. Hepatic expression of human AGT1, the protein encoded by AGXT, by adenoviral vector-mediated gene transfer in Agxt-/- mice normalized urinary oxalate excretion and prevented oxalate crystalluria. Subcellular fractionation and immunofluorescence studies revealed that, as in the human liver, the expressed wild-type human AGT1 was predominantly localized in mouse hepatocellular peroxisomes, whereas the most common mutant form of AGT1 (G170R) was localized predominantly in the mitochondria.

KW - Gene therapy

KW - Knockout mouse

KW - Nephrocalcinosis

KW - Oxalate

KW - Urolithiasis

UR - http://www.scopus.com/inward/record.url?scp=33845323365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845323365&partnerID=8YFLogxK

U2 - 10.1073/pnas.0607218103

DO - 10.1073/pnas.0607218103

M3 - Article

VL - 103

SP - 18249

EP - 18254

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 48

ER -